T1	Participants 292 333	Community-dwelling women ages 50-79 years
T2	Participants 366 452	Women with prior arthroplasty were excluded, yielding a sample size of 26,321 subjects
T3	Participants 454 646	Women who had had hysterectomies (n = 10,272) were randomly assigned to receive 0.625 mg/day conjugated equine estrogens (n = 5,076), or placebo (n = 5,196), with a mean followup of 7.1 years.
T4	Participants 647 920	Those who had not had hysterectomies (n = 16,049) were randomly assigned to receive estrogen plus progestin (n = 8,240), given as 0.625 mg/day conjugated equine estrogens plus 2.5 mg/day medroxyprogesterone acetate, or placebo (n = 7,809), with a mean followup of 5.6 years
T5	Participants 1017 1065	Arthroplasties due to hip fracture were censored
T6	Participants 922 1015	Participants reported hospitalizations, and arthroplasties were identified by procedure codes
